Hormone receptor positive breast tumor

Endocrine Therapy Before Surgery Results in Different Outcomes in Black vs. White Women With Breast Cancer, City of Hope-Led Study Finds

Retrieved on: 
Friday, September 16, 2022

Black women are four times more likely than white women to die of hormone receptor-positive breast cancer.

Key Points: 
  • Black women are four times more likely than white women to die of hormone receptor-positive breast cancer.
  • While neoadjuvant endocrine therapy appeared to benefit Black women with Stage 1 and 2 breast cancer, our findings suggest that it was not beneficial in Black women with more advanced tumors.
  • To examine health outcome differences between Black and white women, Jones and colleagues analyzed 3,521 white women and 365 Black women with Stage 1 through 3 hormone receptor-positive breast cancer from the National Cancer Database.
  • Little is known about the contribution of endocrine therapy resistance to the mortality disparity seen in Black women.

The American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact Award

Retrieved on: 
Monday, October 25, 2021

ATLANTA and NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The American Cancer Society (ACS) and Flatiron Health announced today that the 2021 Real-World Data Impact Awards will support research into health disparities among patients with advanced pancreatic and breast cancer.

Key Points: 
  • ATLANTA and NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The American Cancer Society (ACS) and Flatiron Health announced today that the 2021 Real-World Data Impact Awards will support research into health disparities among patients with advanced pancreatic and breast cancer.
  • "Flatiron Health is honored to partner with ACS to leverage Flatiron's EHR-derived real-world data to advance research toward better and more equitable cancer treatments and outcomes," said Rebecca Miksad, MD, MPH, senior medical director at Flatiron Health.
  • Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow.
  • Flatiron.com @FlatironHealth
    The American Cancer Society is on a mission to free the world from cancer.

City of Hope-Led Research Identifies How the Most Common Type of Breast Cancer Becomes Resistant to Treatment

Retrieved on: 
Thursday, June 24, 2021

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .

Key Points: 
  • City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .
  • About 80% of breast cancer cases are hormone receptor positive, meaning that these cancer cells need estrogen or progesterone to grow, according to the American Cancer Society .
  • Doctors currently treat people with estrogen receptor positive (ER+) breast cancer using therapy that inhibits both estrogen levels and cell cycle activity.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibit

Retrieved on: 
Tuesday, January 19, 2021

In the Nature Medicine publication, Dr. Hickey and colleagues provide scientific evidence supporting a new discovery in breast cancer demonstrating that the androgen receptor acts like a tumor suppressor.

Key Points: 
  • In the Nature Medicine publication, Dr. Hickey and colleagues provide scientific evidence supporting a new discovery in breast cancer demonstrating that the androgen receptor acts like a tumor suppressor.
  • Further, enobosarm, by activating the androgen receptor, has demonstrated antitumor activity in both estrogen receptor targeted endocrine therapy resistant and CDK4/6 inhibitor resistant metastatic human breast cancer models.
  • This study clears up the confusion in the scientific field regarding the role that the androgen receptor is playing in ER+ breast cancer.
  • The Veru breast cancer pipeline includes enobosarm for hormone sensitive metastatic ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer.

H3 Biomedicine, Inc. Presents Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor-positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 8, 2020

H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of three posters at the 2020 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • H3 Biomedicine, Inc. (H3), a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced the presentation of three posters at the 2020 San Antonio Breast Cancer Symposium (SABCS).
  • The presentations include interim data from H3s ongoing Phase 1/2 clinical development program, H3B-6545, a potential first-in-class, orally available Selective ER Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer.
  • Our ongoing evaluation of H3B-6545 underscores our mission to work to develop new oncology therapeutics by unlocking cancer genomics, real-world patient data and biomarkers, said Antonio Gualberto, MD, PhD, Chief Medical Officer of H3.
  • H3B-6545, a first-in-class small molecule selective estrogen receptor covalent antagonist (SERCA) demonstrates activity in tumor models that harbor wild-type or mutant ER.

Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast Cancer

Retrieved on: 
Monday, December 7, 2020

The data presented highlight treatment resistance in estrogen receptor positive (ER-positive), HER-2 negative metastatic breast cancer patients.

Key Points: 
  • The data presented highlight treatment resistance in estrogen receptor positive (ER-positive), HER-2 negative metastatic breast cancer patients.
  • The abstracts, now online, show how this robust platform helps characterize molecular tumor evolution and treatment resistance mechanisms throughout each patients treatment journey.
  • The GuardantINFORM platform is an in silico platform that combines de-identified longitudinal clinical information and genomic data collected from our Guardant360 liquid biopsy test.
  • Guardant Health has launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced stage cancer patients.

Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL for Clinically High Risk, Molecularly Low Risk Stage 2/3 Breast Cancer

Retrieved on: 
Monday, June 8, 2020

This study arm, known as the I-SPY-2 Endocrine Optimization Pilot Protocol (EOP), is focused on patients with molecularly low risk (MammaPrint low risk signature), clinically high risk, hormone receptor positive (HR+), and HER2-negative breast cancer.

Key Points: 
  • This study arm, known as the I-SPY-2 Endocrine Optimization Pilot Protocol (EOP), is focused on patients with molecularly low risk (MammaPrint low risk signature), clinically high risk, hormone receptor positive (HR+), and HER2-negative breast cancer.
  • The selective estrogen receptor degrader (SERD) class of compoundshave demonstrated benefit in HR+ HER2-negative metastatic breast cancer, including tumors with estrogen receptor activating mutations.
  • The EOP study will use an oral SERD as the endocrine therapy backbone.
  • Under the terms of the collaboration agreement, Quantum Leap Healthcare Collaborative is the trial sponsor and manages all study operations.

Biotheranostics presents new studies of the Breast Cancer Index® at the 2020 ASCO conference, expanding its clinical utility as a predictive tool for hormone receptor positive, early-stage breast cancer

Retrieved on: 
Friday, May 29, 2020

Furthermore, results from an ongoing study in collaboration with Yale University (Foldi et al) evaluated the impact of Breast Cancer Index results on patient adherence to extended endocrine therapy.

Key Points: 
  • Furthermore, results from an ongoing study in collaboration with Yale University (Foldi et al) evaluated the impact of Breast Cancer Index results on patient adherence to extended endocrine therapy.
  • Don Hardison, Biotheranostics President and CEO adds, Breast Cancer Index continues to demonstrate its ability to predict which hormone receptor positive patients are likely to benefit from additional anti-estrogen therapy vs those who will not.
  • Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early stage, HR+ breast cancer.
  • Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients.

Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration (“FDA”)

Retrieved on: 
Monday, May 4, 2020

We have had two meetings with FDA and will request another meeting to discuss these data.

Key Points: 
  • We have had two meetings with FDA and will request another meeting to discuss these data.
  • We look forward to providing additional updates on the progress of this potential drug treatment for hormone-receptor (HR)-positive advanced breast cancer, stated Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals.
  • A substantial number of women with advanced HR-positive breast cancer receiving standard treatment experience early disease progression, said Adrian Hepner, Chief Medical Officer of Eagle Pharmaceuticals.
  • Low and inconsistent estrogen receptor inhibition often results in suboptimal treatment, which may lead to faster progression of the disease.

Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index® Test

Retrieved on: 
Wednesday, December 11, 2019

San Diego, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for early-stage, hormone receptor-positive (HR+) breast cancer patients.

Key Points: 
  • San Diego, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Biotheranostics, Inc., announces the launch of its Not Another Minute campaign, revealing how Breast Cancer Index (BCI) is changing the game for early-stage, hormone receptor-positive (HR+) breast cancer patients.
  • Breast Cancer Index is the only commercially-available test that predicts whether a woman is likely to benefit from continuing her anti-estrogen therapy to ten years.
  • Lisa Whitmyer, Biotheranostics VP of Marketing, shares, As a breast cancer survivor myself, taking anti-estrogen therapy can be a life-altering five years.
  • Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early-stage, HR+ breast cancer.